SELLAS Life Sciences (SLS) Liabilities from Discontinued Operations (2014 - 2017)
SELLAS Life Sciences (SLS) posted quarterly Liabilities from Discontinued Operations of 6759000.0 for Q3 2017, up 61.12% year-over-year from 4195000.0 in Q3 2016, and down 22.18% quarter-over-quarter from 8685000.0 in Q2 2017.
SELLAS Life Sciences (SLS) Liabilities from Discontinued Operations (2014 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Liabilities from Discontinued Operations for 4 consecutive years, with 6759000.0 the latest figure, recorded in Q3 2017.
- In Q3 2017, Liabilities from Discontinued Operations rose 61.12% year-over-year to 6759000.0; the TTM figure through Sep 2017 stood at 6759000.0 (up 61.12% YoY), while the FY2016 annual figure was 6059000.0, up 2.26% from the prior year.
- Liabilities from Discontinued Operations slipped to 6759000.0 in Q3 2017 per SLS's latest filing, from 8685000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 10045000.0 in Q1 2017 and bottomed at 3727000.0 in Q2 2016.
- Historically, Liabilities from Discontinued Operations has averaged 6474800.0 across 4 years, with a median of 6409000.0 in 2016.
- Annual changes were most pronounced in 2016 — Liabilities from Discontinued Operations tumbled 45.5% — and 2017, when it jumped 133.03%.
- SELLAS Life Sciences' Liabilities from Discontinued Operations stood at 7169000.0 in 2014, then decreased by 17.35% to 5925000.0 in 2015, then grew by 2.26% to 6059000.0 in 2016, then rose by 11.55% to 6759000.0 in 2017.
- Business Quant data shows SLS's Liabilities from Discontinued Operations at 6759000.0 in Q3 2017, 8685000.0 in Q2 2017, and 10045000.0 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 6.76 Mn |
| Sep 30, 2017 | 6.76 Mn |
| Jun 30, 2017 | 8.69 Mn |
| Jun 30, 2017 | 8.69 Mn |
| Mar 31, 2017 | 10.05 Mn |
| Mar 31, 2017 | 10.05 Mn |
| Dec 31, 2016 | 6.06 Mn |
| Dec 31, 2016 | 6.06 Mn |
| Sep 30, 2016 | 4.20 Mn |
| Sep 30, 2016 | 4.20 Mn |
| Jun 30, 2016 | 3.73 Mn |
| Jun 30, 2016 | 3.73 Mn |
| Mar 31, 2016 | 4.49 Mn |
| Mar 31, 2016 | 4.49 Mn |
| Dec 31, 2015 | 5.93 Mn |
| Dec 31, 2015 | 5.93 Mn |
| Sep 30, 2015 | 7.70 Mn |
| Sep 30, 2015 | 7.70 Mn |
| Dec 31, 2014 | 7.17 Mn |
| Dec 31, 2014 | 7.17 Mn |